Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval
fiercepharma | June 05, 2018
With an FDA approval for Fulphila, the first U.S. biosimilar to Amgen's Neulasta, Mylan will have its chance to launch a biosim to one of the biggest drug targets in the U.S. market.It's good news for Mylan, which sees biosimilars as a rescue from the tough market for typical generic drugs. Not so good for Amgen, which reaped $3.9 billion from Neulasta in the U.S. last year and already faces biosimilar competition for the shorter-acting version, Neupogen. Announcing its FDA approval late Monday, Mylan said it will launch the Neulasta copycat, now dubbed Fulphila, in the coming weeks. The company didn't immediately disclose pricing. A white blood cell booster for cancer patients after chemotherapy, Neulasta brought in $3.9 billion in the U.S. last year, making it the second-largest loss of exclusivity in pharma this year.